SUSTAIN Clinical Trial Program Overview
The SUSTAIN clinical trial program was a comprehensive phase 3 development program evaluating once-weekly subcutaneous semaglutide (0.5 mg and 1.0 mg) across the spectrum of type 2 diabetes, demonstrating superior glycemic control and weight loss compared to all active comparators, with proven cardiovascular benefit in high-risk patients. 1
Program Structure and Scope
The SUSTAIN program enrolled over 8,000 patients across multiple trials (SUSTAIN 1-7), testing semaglutide in diverse clinical scenarios:
- Early T2DM managed with diet and exercise alone
- Established T2DM inadequately controlled on 1-3 oral antidiabetic drugs
- Advanced disease requiring insulin therapy
- Patients spanning 33 countries with varied demographic and clinical characteristics 2, 3
Glycemic Efficacy Results
Subcutaneous semaglutide 1.0 mg achieved HbA1c reductions of 1.5-1.8% after 30-56 weeks, significantly outperforming all comparators tested 2:
- Superior to sitagliptin, liraglutide, exenatide ER, dulaglutide, canagliflozin, and insulin glargine
- The 0.5 mg dose demonstrated HbA1c reductions of approximately 1.0-1.5%
- 58-83% of patients achieved ≥1.0% HbA1c reduction across trials 4
Specific Comparator Data
When combined with basal insulin (±metformin), semaglutide demonstrated robust efficacy in a 30-week trial of 397 patients with mean baseline HbA1c of 8.3-8.4%:
- Semaglutide 1.0 mg reduced HbA1c by 1.7% vs. 0.2% with placebo (difference: -1.6%, p<0.0001)
- 73% achieved HbA1c <7% with 1.0 mg vs. 13% with placebo 1
Weight Loss Outcomes
Semaglutide produced superior weight reduction compared to all active comparators, with dose-dependent effects 2, 3:
- 1.0 mg dose: 4.7-6.0 kg weight loss over 30 weeks
- 0.5 mg dose: 3.2-3.5 kg weight loss
- 38-59% of patients on 1.0 mg achieved combined endpoint of ≥1.0% HbA1c reduction AND ≥5.0% weight loss 4
- 45-66% achieved ≥5.0% weight loss with 1.0 mg dose alone
In the basal insulin combination trial, mean weight changes were -6.0 kg (1.0 mg) and -3.5 kg (0.5 mg) vs. -1.2 kg with placebo 1.
SUSTAIN 6: Cardiovascular Outcomes Trial
SUSTAIN 6 demonstrated that semaglutide significantly reduces major adverse cardiovascular events (MACE) in high-risk patients with T2DM 1:
Trial Design
- 3,297 patients with inadequately controlled T2DM and established atherosclerotic CVD
- Median observation: 2.1 years
- Double-blind, placebo-controlled design
- Patients ≥50 years with established CVD or ≥60 years with CV risk factors
Patient Characteristics
- Mean age: 65 years; 61% male
- Mean diabetes duration: 13.9 years; mean BMI: 33 kg/m²
- 58.8% had established CVD without CKD
- 24% had heart failure, 93% hypertension, 33% prior MI
Primary Results
Hazard ratio for MACE: 0.74 (95% CI: 0.58-0.95), representing a 26% relative risk reduction 1:
- MACE occurred in 6.6% with semaglutide vs. 8.9% with placebo
- Non-fatal stroke: HR 0.61 (95% CI: 0.38-0.99) - significant reduction
- Non-fatal MI: HR 0.74 (95% CI: 0.51-1.08) - trend toward benefit
- CV death: HR 0.98 (95% CI: 0.65-1.48) - neutral
This established semaglutide as one of only four GLP-1 RAs proven to reduce MACE, alongside liraglutide (LEADER), dulaglutide (REWIND), and efpeglutide 5, 6.
Safety and Tolerability Profile
Comprehensive safety analysis across SUSTAIN trials (n=3,150 on semaglutide) revealed 7:
Gastrointestinal Effects
- Most common adverse events: GI disorders in 41.9% vs. 22.0% with comparators
- Predominantly occurred during initiation and dose escalation phases
- Decreased with continued therapy
- Nausea, vomiting, diarrhea were dose-dependent
Other Safety Findings
- Low hypoglycemia risk when used without insulin or sulfonylureas 5
- Acute pancreatitis rates similar to comparators
- Malignant neoplasm rates comparable
- Cholelithiasis incidence higher vs. placebo - monitor for gallbladder symptoms
- Small pulse rate increases observed without increased arrhythmia rates
- Fatal adverse event incidence similar between groups
Important Caveat
Diabetic retinopathy complications were increased in SUSTAIN 6, particularly in patients with rapid glycemic improvement - this requires careful monitoring in patients with pre-existing retinopathy 7.
Renal Effects
The SUSTAIN program demonstrated renal benefits, including prevention of new-onset macroalbuminuria and reduced urinary albumin excretion 5. Subsequent data from the FLOW trial (not part of SUSTAIN but using same drug) showed semaglutide 1.0 mg weekly significantly reduced major kidney disease events in patients with T2DM and CKD 5.
Clinical Implications
Semaglutide represents the most efficacious GLP-1 RA for both glycemic control and weight loss, with proven cardiovascular benefit in high-risk populations 5, 2:
- First-line consideration for patients with T2DM and obesity
- Preferred agent for patients with established CVD or high CV risk
- Requires slow titration (0.25 mg × 4 weeks → 0.5 mg × 4 weeks → 1.0 mg) to minimize GI side effects 1
- Monitor for diabetic retinopathy progression, especially with baseline retinopathy
- Screen for gallbladder symptoms during treatment
The SUSTAIN program established subcutaneous semaglutide as a cornerstone therapy across the T2DM treatment spectrum, from early disease to advanced insulin-requiring patients, with benefits extending beyond glycemic control to cardiovascular risk reduction and substantial weight loss 3.